Highest-materiality recent filing
Covista Q3 revenue up 4.5%, enrollment over 100k; raises FY2026 revenue and EPS guidance
Revenue $487M (+4.5% YoY); adjusted EPS $1.98 vs $1.92; GAAP EPS $1.20 vs $1.59.
Covista targets 7-10% revenue CAGR, >120k enrollment by FY2029 in new strategy
Financial targets through FY2029: revenue CAGR 7-10%, adjusted EPS CAGR 10-14%, enrollment >120,000.
Covista enters $510M term loan refinancing, redeems $405M senior notes
New $510M 2026 Term Loans issued under amended credit agreement, maturing March 2, 2033.
Covista unveils 'Purpose at Scale' 3-year plan; FY26 reaffirmed, ticker to CVSA
Introduces 'Purpose at Scale' strategy for FY27-29 targeting revenue growth 6-11% and adj. EPS growth 9-16% annually.
Adtalem rebrands as Covista, ticker CVSA; launches research platform and investor day
Name changed from Adtalem Global Education to Covista Inc. effective Feb 5, 2026; NYSE ticker changes to CVSA effective Feb 24.
Adtalem completes $150M buyback, authorizes new $750M repurchase program
Completed $150M accelerated share repurchase program; repurchased 1.6M shares.
Adtalem FY2025 revenue $1.79B (+12.9%), adj EPS $6.67 (+33%); FY2026 guidance $7.60-$7.90 adj EPS
Q4 revenue $457.1M (+11.5%), total enrollment 91,780 (+10.2% YoY).
Adtalem Q3 FY2025 EPS $1.59 ($1.92 adj.), revenue $466.1M +12.9%; raises FY guidance
Revenue $466.1M (+12.9% YoY); diluted EPS $1.59 (adj. $1.92, +28% YoY); net income $60.8M.
Adtalem authorizes $150M new buyback; completes $300M prior program, returns $763M since 2022
Board authorized $150M share repurchase program, expiring May 2028.
Adtalem Q2 FY2025 EPS $1.98 ($1.81 adjusted), revenue up 13.9%, guidance raised
Revenue $447.7M (+13.9% YoY); GAAP net income $75.9M ($1.98 diluted EPS).
Adtalem CEO Steve Beard elected Chairman; Q1 enrollment up 11.2% to 90,000+
Steve Beard, President and CEO, unanimously elected Chairman of the Board effective Nov. 13, 2024.
Adtalem Q1 FY2025: Revenue up 13.2%, adj. EPS $1.29 (+38.7% YoY); raises FY guidance
Revenue $417.4M (+13.2% YoY); net income $46.2M vs $10.6M prior year; adj. EPS $1.29 vs $0.93.
Adtalem Q4 rev $409.9M (+12.4% YoY); FY25 EPS guidance $5.60-$5.85 above prior projections
FY24 diluted EPS $3.39; adjusted EPS $5.01 (+19% YoY). Revenue $1,584.7M (+9.2% YoY).
Adtalem Q3 revenue up 11.8% YoY; adjusted EPS $1.50, raises FY2024 guidance
Revenue $412.7M (+11.8% YoY); total enrollment 85,809 (+7.8% YoY).
Total enterprise enrollment up 6% YoY as of Dec 31, 2023; Chamberlain up 7%, Walden up 8%.
Adtalem Q2 revenue +8.4% to $393.2M, raises FY guidance; short seller report disclosed
Revenue $393.2M (+8.4% YoY); total enrollment 81,772 (+6.2%); Chamberlain enrollment +6.6%, Walden +7.9%.
Adtalem Q1 FY2024: revenue $368.8M, adjusted EPS $0.93; FY guidance raised
GAAP net income $10.6M ($0.25 diluted EPS); adjusted EPS $0.93, up 3.3% YoY.
Adtalem FY2023 adjusted EPS $4.21, up 35% YoY; raises FY2024 guidance low end
FY2023 adjusted EPS $4.21 (+35% YoY); GAAP EPS $2.05; Q4 adjusted EPS $1.03.
Adtalem unveils Growth with Purpose strategy and long-term financial targets through FY2026
Reaffirms FY2023 guidance: revenue $1.40B-$1.45B, adjusted EPS $4.05-$4.20.
Adtalem Q3 revenue $369.1M (+1.3% YoY); adjusted EPS $1.13 (+34.5%)
Adjusted EPS $1.13 up 34.5% YoY; GAAP EPS $1.00 vs $7.04 prior year on prior-year gain.
Adtalem Q2 revenue down 2.1% but adjusted EPS up 56%; margins expand, guidance reaffirmed
Revenue $363.3M (-2.1% YoY); diluted EPS $0.52 vs $0.36; adjusted EPS $1.17 vs $0.75 (+56%).
Adtalem board elects Michael Malafronte as Chairman, succeeding Lisa Wardell
Michael Malafronte elected Chairman effective Nov. 9, 2022, succeeding Lisa Wardell who continues as director.
Adtalem Q1 revenue $354.6M (+22.7%); adjusted EPS $0.88 (+151%); margins expand
Revenue $354.6M up 22.7% YoY; diluted EPS $0.05 vs loss of $1.17; adjusted EPS $0.88 up 151.4%.
Adtalem Q4 revenue +61.6% to $361.2M; FY2022 adj. EPS $3.24 (+40% YoY); FY2023 guidance $3.95-$4.20
Q4 revenue $361.2M (+61.6% YoY); GAAP EPS $0.18 flat; adjusted EPS $1.31 vs $0.48 YoY.
Adtalem Q3 EPS $7.09; raises FY22 adjusted EPS guidance to $3.15-$3.35
Revenue $365.6M (+58.8% YoY); adjusted diluted EPS from cont. ops $0.87 vs $0.60 prior year.
Adtalem retires $373.3M of 5.500% Notes, 46.67% of outstanding
$373,333,000 of 5.500% Senior Notes due 2028 validly tendered and accepted for purchase.
Adtalem offers up to $373.3M for 5.5% notes due 2028; enters $150M ASR with Morgan Stanley
Offer to purchase up to $373.3M of 5.500% Senior Notes due 2028 at 100% of principal plus accrued interest.
Adtalem completes $1B sale of Financial Services segment; plans $770M debt paydown
Sold ACAMS, Becker Professional Ed, and OnCourse Learning to Wendel Group & Colibri Group for $1B cash.
Adtalem announces $150M ASR, $300M buyback authorization; plans $770M debt paydown from divestiture
$150M accelerated share repurchase (ASR) program funded with existing cash.
Adtalem Global Education Reports Fiscal Q2 2022 Results, Revises Full-Year Guidance
Revenue rose 58.4% to $371.2M, driven by the Walden acquisition; diluted EPS fell to $0.36 from $0.44.
On November 13, 2024, the Board of Directors (the “Board”) of Adtalem Global Education Inc. (“Adtalem” or “the Company”) unanimously elected Stephen W. Beard, Adtalem’s President and Chief Executive Officer, as Chairman of the Board effective immediately.
Mr. Malafronte will continue to serve on the Board as Lead Independent Director, Chair of the Compensation Committee, and a member of the Academic Quality Committee.
reporting that Dr. John Danaher President, Medical & Veterinary was leaving Adtalem effective September 15, 2023.
The Adtalem Board of Directors (the “Board”) has appointed Dr. Betty Vandenbosch as an independent member of Adtalem’s Board effective January 8, 2024
On September 6, 2023, Adtalem Global Education Inc. (“Adtalem” or “the Company”) announced that Dr. John Danaher, President, Adtalem Medical & Veterinary, will be leaving Adtalem effective September 15, 2023.
On November 10, 2022, Adtalem Global Education Inc. (“Adtalem”) issued a press release announcing that its Board of Directors (the “Board”) unanimously elected Michael W. Malafronte, 48, as Chairman of the Board effective November 9, 2022.
succeeds Ms. Lisa W. Wardell as Chairman of the Board.
The Adtalem Board of Directors (the “Board”) has appointed Mr. William (“Liam”) Krehbiel as an independent member of Adtalem’s Board effective June 6, 2022.
On May 23, 2022, Adtalem Global Education Inc. (“Adtalem”) announced the appointment of Michael Betz as President of Walden University, effective as of May 17, 2022.
On April 18, 2022, Adtalem Global Education Inc. (“Adtalem”) appointed Manjunath Gangadharan (39) as Vice President, Chief Accounting Officer and principal accounting officer of Adtalem, effective as of April 18, 2022.
On October 18, 2021, Adtalem Global Education Inc. (“ATGE” or “the Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission reporting that effective October 18, 2021, Mr. Robert J. Phelan, who had been serving as ATGE’s interim chief financial officer since April 2021, had been appointed ATGE’s chief financial officer.
Mr. Robert J. Phelan, who had been serving as ATGE’s interim chief financial officer since April 2021, had been appointed ATGE’s chief financial officer.
Max materiality 0.85 · Median 0.65 · Most common event earnings